exagen-logo-black.png
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
12. Dezember 2024 09:00 ET | Exagen Inc.
CARLSBAD, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the completion of its 1,000,000th AVISE CTD test, marking a significant...
Exagen logo_440x386 (1).jpg
Exagen Inc. Expands In-Network Benefit with Additional 22.7 Million Lives
22. März 2022 16:06 ET | Exagen Inc.
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® tests will soon surpass 90 million lives as...
Exagen logo_440x386 (1).jpg
Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collaboration to Develop Novel Patented Molecular Signatures for Rheumatoid Arthritis Biologic Therapeutic Selection
09. Januar 2022 12:00 ET | Exagen Inc.
SAN DIEGO, Jan. 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Queen Mary University of London, announced today the execution of a...
Exagen logo_440x386 (1).jpg
Exagen Inc. to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
17. November 2021 16:05 ET | Exagen Inc.
SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Piper Sandler 33rd Annual Virtual...
Exagen logo_440x386 (1).jpg
Exagen Showcases Eight Scientific Presentations at ACR’s Virtual Annual Meeting in November 2021
21. Oktober 2021 16:05 ET | Exagen Inc.
SAN DIEGO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today it will be presenting new scientific research at the...
Exagen_Full_CMYK_Print.jpg
Exagen Inc. Reports Second Quarter 2020 Results
28. Juli 2020 07:00 ET | Exagen Inc.
Testing Experiencing Monthly Sequential ImprovementRecord Gross Margins of 63% SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming...
Exagen_Full_CMYK_Print.jpg
Exagen Inc. AVISE Testing Now Covered and In-Network with TRICARE East
27. Juli 2020 16:05 ET | Exagen Inc.
SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced...
Exagen_Full_CMYK_Print.jpg
Exagen Inc. Reports Third Quarter 2019 Results
12. November 2019 16:05 ET | Exagen, Inc.
AVISE® Testing Revenue Drives 27% Revenue Growth SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients...
Improved Laboratory Testing with EC4d Can Help Physicians Monitor Patients with Lupus
12. Juni 2017 07:43 ET | Exagen Diagnostics, Inc.
ALBUQUERQUE, NM and SAN DIEGO, CA, June 12, 2017 (GLOBE NEWSWIRE) -- Exagen Diagnostics, Inc., home of AVISE® testing, announced the nationwide availability of a new test leveraging the power of...